Sitaglu Met (Sitagliptin/Metformin HCl) 50/1000mg tablets
₨ 1,125
Payment Methods:
Description
Sitaglu Met (Sitagliptin 50mg + Metformin HCl 1000mg) Tablets
Powerful Dual Therapy for Type 2 Diabetes Management
Sitaglu Met combines Sitagliptin (DPP-4 inhibitor) and Metformin HCl (biguanide) to provide effective blood sugar control in adults with Type 2 diabetes. This combination works by enhancing insulin production, reducing glucose production in the liver, and improving insulin sensitivity, leading to better diabetes management.
Key Benefits
✔ Effectively Lowers Blood Sugar – Helps regulate glucose levels throughout the day.
✔ Enhances Natural Insulin Production – Stimulates insulin release when needed.
✔ Reduces Glucose Production – Limits sugar release from the liver.
✔ Supports Weight Management – Helps prevent weight gain associated with diabetes.
✔ Reduces the Risk of Hypoglycemia – Works with the body’s natural insulin response.
How to Use
- Take one tablet twice daily, or as prescribed by your doctor.
- Swallow whole with water; do not crush or chew.
- Best taken with meals to reduce stomach discomfort.
- Follow your doctor’s dietary and exercise recommendations for optimal results.
Important Information
- Regular blood sugar monitoring is recommended.
- May cause mild stomach upset in the beginning; take with food to minimize discomfort.
- Not for patients with severe kidney disease or Type 1 diabetes.
- Avoid excessive alcohol consumption, as it may increase the risk of lactic acidosis.
- Consult a doctor before use if pregnant or breastfeeding.
Sitaglu Met is a highly effective diabetes treatment that helps patients maintain stable blood sugar levels, improve insulin function, and reduce diabetes-related risks.
Customer Reviews
Related Products
Rasasi Chastity Pour Femme Deodorant Body Spray For Women 200ml
In stock
Remy Marquis Original Shalis de Man Paris Deodorant Spray 175ml
In stock
Vaseline Blueseal Aloe Fresh Light Hydrating Jelly 50ml
In stock


FEEDERS
Reviews
Clear filtersThere are no reviews yet.